GSK250110C35000
- 0.03
- +0.01+50.00%
GlaxoSmithKline Newsroom
Why CureVac (CVAC) Shares Are Volatile
Travel Vaccines Industry Forecast 2024-2032, Featuring Strategic Analysis of GlaxoSmithKline, Merck & Co, Sanofi, Pfizer, CSL Limited, Bavarian Nordic, Roche, Abbott Labs, AstraZeneca, Janssen Pharma & More
Ouro Medicines Launches to Define the Future of Treatment for People With Immune-Mediated Diseases
GSK's Shingrix New Prefilled Syringe Presentation Accepted for Review by US FDA
Pharma Companies Welcome New Year With 583 Drug Price Hikes so Far
Drugs Not Selected for Medicare Price Negotiation Nearly Doubled - Report
Update: Market Chatter: GSK Reportedly in Advanced Talks to Buy US Biotech IDRx
FDA Label Warning Threatens GSK's RSV Vaccine Sales -- Market Talk
Sector Update: Health Care Stocks Higher in Afternoon Trading
Sector Update: Health Care
Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies
Top Midday Stories: Meta Platforms to Test EBay Listings on Facebook Marketplace; Quantum Computing Stocks Fall After Nvidia CEO's Comments
Vir Biotechnology, Once a Hot Covid Stock, Finds New Path Forward in Cancer -- Barrons.com
Update: Market Chatter: GSK Nears Deal to Acquire US Biotech IDRx for Up to $1 Billion
GSK Nearing $1 Billion Deal to Acquire US Biotech IDRx, FT Reports
Express News | 'GSK Nears $1bn Deal for Biotech Developing Drug for Rare Tumour' - Financial Times
Pfizer And GSK's RSV Vaccines Safety Labels Updated, FDA Adds Warning For Rare Neurological Disorder
The FDA states that GlaxoSmithKline (GSK.US) and Pfizer (PFE.US) RSV vaccines must include warnings about the rare risk of paralysis.
The FDA stated that a vaccine produced by GlaxoSmithKline (GSK.US) and Pfizer (PFE.US) must include a warning about the potential increased risk of a rare neurological side effect.
Arbutus Could Benefit From Big Pharma Bird Flu Vaccines: Jefferies
US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally